New CNS-active drugs which are second-generation valproic acid: Can they lead to the development of a magic bullet?

Current Opinion in Neurology

Volumn 16, Issue 2, 2003, Pages 203-211

  Isoherranen, Nina ^a   Yagen, Boris ^a,b   Bialer, Meir ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiepileptic drug; Derivatives and analogues of valproic acid; Second generation antiepileptic drugs; Valproic acid

Indexed keywords

2 ISOPROPYLVALERAMIDE; 3 METHYLBUTANAMIDE; AMIDE; ISOVALERAMIDE; N METHYLTETRAMETHYLCYCLOPROPANECARBOXAMIDE; SPD 421; TAURINE DERIVATIVE; UNCLASSIFIED DRUG; VALNOCTAMIDE; VALPROIC ACID; VALPROIC ACID DERIVATIVE; VALROCEMIDE;

ANTICONVULSANT ACTIVITY; BIPOLAR DISORDER; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EPILEPSY; FOLLOW UP; HUMAN; LIVER TOXICITY; MIGRAINE; REVIEW; TERATOGENICITY;

AMIDES; ANTICONVULSANTS; BIPOLAR DISORDER; EPILEPSY; HUMANS; MIGRAINE DISORDERS; VALPROIC ACID;

EID: 0242499953     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200304000-00014     Document Type: Review

References (60)

1. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16:695-714. This paper reviews the therapeutic use (efficacy and safety) of VPA, including a concise update on VPA's mechanisms of action, pharmacokinetic properties and interaction potential.
2. Loscher W. Valproate. Basel, Switzerland: Birkhauser Verlag; 1999.
3. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16:669-694.
4. Bialer M. New antiepileptic drugs currently in clinical trials: is there a strategy in their development? Ther Drug Monit 2002; 24:85-90.
5. Nau H, Siemens H. Differentiation between valproate-induced antiepileptic effect, teratogenicity and hepatotoxicity. Pharm Weekbl Sci 1992; 14:101-105.
6. Bojic U, Ehlers K, Ellerbeck U, et al. Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic center. Eur J Pharmacol 1998; 353:289-299.
7. Tang W, Palaty J, Abbott FS. Time course of α-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal γ-aminobutyric acid levels in comparison to valproic acid. J Pharmacol Exp Ther 1997; 282:1163-1172.
8. Tang W, Borel AG, Fujimiya T, et al. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesiculas steatosis and glutathione status. Chem Res Toxicol 1995; 8:671-682.
9. Neuman MG, Shear NH, Jacobsen-Brown PM, et al. CYP2E1 mediated modulation of valproic acid-induced hepatocytotoxicity. Clin Biochem 2001; 34:211-218. This paper presents evidence that CYP2E1 catalyzes the formation of hepatotoxic VPA metabolites and that 4-ene-VPA is a more potent hepatotoxin than its parent compound. The authors conclude that CYP2E1 inducers enhance VPA's hepatotoxicity and that it may be possible to reduce the risk of hepatotoxicity by blocking metabolism via β-oxidation pathways.
10. Grillo MP, Chiellini G, Tonerli M, Benet LZ. Effect of alpha-fluorination of valproic acid on valproyl-S-acyr-CoA formation in vivo in rats. Drug Metab Dispos 2001; 29:1210-1215. In this study the hypothesis that acyl-coenzyme A conjugation of VPA and its 4-ene-metabolite leads to coenzyme A depletion in the liver and to consequent hepatotoxicity was challenged. The α-F-VPA was used as a probe for studying the correlation between acyl-coenzyme A conjugations and hepatotoxicity. The authors suggest that the lack of hepatotoxic effects of the α-F-4-ene-VPA may be due to the lack of formation of the coenzyme A thioester conjugate rather than a block in the formation of the 2,4-diene metabolite.
11. Nau H, Hauck R-S, Ehlers K. Valproic acid induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991; 69:310-321.
12. Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991; 20:114-122.
13. Morre M, Keane PE, Vernieres JC, et al. Valproate: recent findings and perspectives. Epilepsia 1984; 25 (Suppl 1);S5-S9.
14. Keane PE, Simiand J, Mendes E, et al. The effects of analogues of valproic acid on pentylenetetrazol induced seizures and brain GABA synthesis in mice. Neuropharmacology 1983; 22:875-879.
15. Losher W, Nau H. Valproic acid: metabolite concentrations in plasma and brain, antiepileptic activity, and effects on GABA metabolism during subacute treatment in mice. Arch Int Pharmacodyn Ther 1982; 257:20-31.
16. Liu M-J, Pollack GM. Pharmacokinetics and pharmacodynamics of valproate analogues in rats: IV. Antiepileptic action and neurotoxicity of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid. Epilepsia 1994; 35:234-243.
17. 2(E)-valproate in animals. Pharm Weekbl Sci 1992; 14:139-143.
18. 2-(E)-valproate) in healthy male volunteers. Pharm Weekbl Sci 1992; 20:114-122.
19. Palaty J, Abbott FS. Structure activity relationships of unsaturated analogues of valproic acid. J Med Chem 1995; 38:3398-3406.
20. Nau H, Ellerbeck U, Radatz M, et al. A new analogue of valproic acid with improved anticonvulsant properties and low teratogenic and neurotoxic potential in experimental animals [abstract]. Epilepsia 1998; 39 (Suppl 6):42.
21. Elmazar MMA, Hauck R-S, Nau H. Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid. J Pharm Sci 1993; 82:1255-1258.
22. Bojic U, Elmazar MMA, Hauck R-S, et al. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem Res Toxicol 1996; 9:866-870.
23. Scott KR, Adesioye S, Ayuh PB. Synthesis and evaluation of amino analogues of valproic acid. Pharm Res 1994; 11:571-574.
24. Bialer M, Hai-Yehia A, Badir K, Hadad S. Can we develop improved derivatives of valproic acid? Pharm World Sci 1994; 16:2-6.
25. Badir K, Haj-Yehia A, Vree TB, et al. Pharmacokinetics and anticonvulsant activity of three mono-esteric prodrugs of valproic acid. Pharm Res 1991; 8:750-753.
26. Hadad S, Vree TB, Van der Kleijn E, et al. Pharmacokinetic analysis of esteric prodrugs of valproic acid. J Pharm Sci 1992; 81:1047-1050.
27. Hadad S, Vree TB, Van der Kleijn E, et al. Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid. Biopharm Drug Disposit 1993; 14:51-59.
28. Kehler J, Hengen HI, Sanchez C. Novel phosphinic and phosphonic acid analogues of the anticonvulsant valproic acid. Bioorg Med Chem Lett 2000; 10:2547-2548.
29. Bello-Ramirez A-M, Carreon-Garabito BY, Nava-Ocambo AA. Do structural properties explain the anticonvulsant activity of valproate metabolites? A QSAR study. Epilepsia 2002; 45:475-481.
30. Haj-Yehia A, Hadad S, Bialer M. Pharmacokinetic analysis of the structural requirements for forming 'stable' analogues of valpromide. Pharm Res 1992; 9; 1058-1063.
31. Isoherranen N, Yagen B, Woodhead J, et al. Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents Br J Pharmacol 2003; 138:602-613. This paper describes the anticonvulsant profile of PID in an enantioselective manner. Mechanistic studies are included and enantioselective pharmacokinetics are studied in plasma and brain. Enantiomer-enantiomer interaction PK and PD was also investigated.
32. Isoherranen N, Klein B, Roeder M, et al. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharm Res; (in press).
33. Spiegelstein O, Yagen B, Levy RH, et al. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm Res 1999; 16:1582-1588.
34. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fifth Eilat conference (EILAT V). Epilepsy Res 2001; 43:11-58. A thorough summary of the advances in clinical studies of new AEDs including clinical data on NPS 1776, DP-VPA and valrocemide.
35. Isoherranen N, White HS, Finnell RH, et al. Anticonvulsant profile and teratogenicity of N-methyl-tetamethylcyclopropyl carboxamide: a new anti-epileptic drug. Epilepsia 2002; 43:115-126. This article describes the antiepileptic profile of MTMCD and its metabolite TMCD in rodent models. It also includes teratogenicity evaluation, mechanistic studies and measurements of plasma and brain concentrations of MTMCD and TMCD.
36. Bialer M, Hadad S, Kadry B, et al. Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropane analogues of valpromide. Pharm Res 1996; 13:284-289.
37. Redecker C, Altrup U, Hoppe D, et al. Effects of valproate derivatives: I. Antiepileptic efficacy of amides, structural analogs and esters. Neuropharmacology 2000; 39:254-266.
38. Isoherranen N, Spigelstein O, Yagen B, et al. Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurine derivatives [abstract]. Epilepsia 2002; 43 (Suppl 7):188.
39. Isoherranen N, Woodhead JH, White HS, Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia 2001; 42:831-836. This study summarizes the preclinical spectrum of activity of valrocemide and gives an indication for its possible clinical uses in patients with epilepsy.
40. Rekatas GV, Tan E, Demopoulos VJ, et al. Synthesis of GABA-valproic acid derivatives and evaluation of their anticonvulsant and antioxidant activity. Arch Pharm Pharm Med Chem 1996; 329;393-398.
41. Bialer M, Johannessen SI, Kupfeberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference (EILAT VI). Epilepsy Res 2002; 51;31-71. A comprehensive summary of the current status of new AEDs in clinical trials including data on SPD421 (DP-VPA) and valrocemide.
42. Chatterjie N, Alexander G, Wang H. Synthesis of valproic acid amides of a melatonin derivative, a piracetam and amantadine for biological tests. Neurochem Res 2001; 26:1171-1176.
43. Masereel B, Rolin S, Abbate F, et al. Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem 2002; 45:312-320. This study shows a series of aromatic/heterocyclic sulfonamides incorporating valproyl moieties that were designed by combining VPA and sulfonamides in order to add carbonic anhydrase inhibition to the mechanisms of action of the second-generation VPA. Four new compounds were synthesized that may be considered as lead compounds for developing new derivatives of VPA.
44. Labiner DM. DP-VPA. D-Pharm Curr Opin Invest Drugs 2002; 3:921-923. A manuscript describing the basic pharmacology, current status of development, results of clinical trials and future directions in the use of SPD421 (DP-VPA) in CNS disorders.
45. Redecker C, Altrup U, Hoppe D, et al. Effects of valproate derivatives: II. Antiepileptic efficacy in relation to chemical structures of valproate sugar esters. Neuropharmacology 2000; 39:267-281.
46. Armand V, Louvel J, Pumain R, et al. Effects of various valproic acid derivatives on low-calcium spontaneous epileptiform activity in hippocampal slices. Epilepsy Res 1995; 22:185-192.
47. 2+ in rat entorhinal cortex-hippocampus slices. Epilepsy Res 1998; 32:345-355.
48. Giannola LI, Lamartina L, de Caro V. Synthesis and characterization of aminoacidic pro-drugs of valproic acid. Pharmazie 1998; 53:829-834.
49. Blaheta RA, Nau H, Michaelis M, et al. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 2002; 9:1417-1433. This paper is a thorough review related to VPA's antitumor activity and to its teratogenicity. The authors suggest that VPA's antitumor activity is related to its teratogenicity and describe the structure-activity relationship studies on VPA's teratogenicity and anticancer activity.
50. Lammer EJ, Sever LE, Oakley GP Jr. Teratogen update: valproic acid. Teratology 1987; 35:465-473.
51. Kaneko S, Battino D, Anderman E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33:145-158.
52. Finnell RH, Bennett GD, Karras SB. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 1988; 38:313-320.
53. Nau H. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse. Teratology 1986; 33:21-27.
54. Lampen A, Carlbers C, Nau H. Peroxisome proliferator-activated receptor δ is a specific sensor for teratogencic valproic acid derivatives. Eur J Pharmacol 2001; 431:25-33. This article describes a specific sensor for teratogenic VPA derivatives that may be of great usefulness in screening antiepileptic VPA derivatives for teratogenicty. The authors suggest that peroxisome proliferator receptor δ is a specific sensor but not a receptor for VPA-induced teratogenicity.
55. Finnell RH, Wlodarczyk BC, Craig JC, et al. Strain-dependant alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. Am J Med Genet 1997; 70:303-311.
56. Spiegelstein O, Bialer M, Radatz M, et al. Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid. Chirality 1999; 11:645-652.
57. Radatz M, Ehlers K, Yagen B, et al. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998; 30:41-48.
58. Anderson GD, Acheampong AA, Wilensky AJ, et al. Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 1992; 33:736-742.
59. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 1999; 24:87-92.
60. Bialer M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J Control Release 1999; 62:187-192.